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Abstract
Palmitoylation of cysteines 3 and 5 is necessary for targeting Lck to lipid rafts and is needed for Lck function in T cell
receptor (TCR) signaling. Point mutations of cysteines 3 and 5 result in a form of Lck that fails to associate with the
plasma membrane, which limits the usefulness of this genetic approach to address the role of palmitoylation in the
distribution of Lck within the plasma membrane. To circumvent this problem, we sought to identify a palmitic acid
analogue that would enable plasma membrane association of Lck, but not facilitate its localization within lipid rafts. Here
we examined the effects of the heteroatom-substituted analogue of palmitic acid, 13-oxypalmitic acid (13-OP), on Lck
subcellular localization and function. 13-OP is similar in chain length to palmitic acid, but possesses reduced
hydrophobicity. We found that treatment of cells with 13-OP inhibited incorporation of g-[125I]iodopalmitate into Lck.
13-OP inhibited localization of Lck to lipid rafts without altering its membrane localization. Consistent with the
dissociation of Lck from rafts, treatment with 13-OP abolished Lck association with the GPI-anchored protein, CD48, but
not the transmembrane glycoprotein CD4. Jurkat T cells treated with 13-OP showed marked reduction in tyrosine
phosphorylation and activation of mitogen-activated protein kinase upon TCR stimulation. In conclusion, the less
hydrophobic analogue of palmitate, 13-OP, alters the normal acylation of Lck that provides Lck with the necessary
hydrophobicity and tight packing order required for inclusion in lipid rafts. ; 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Lck is a member of the Src family of non-receptor
protein tyrosine kinases. It is expressed primarily in
T lymphocytes and natural killer (NK) cells and is
activated immediately following T cell antigen recep-
tor (TCR) stimulation. Lck is essential for signaling
through the TCR as T cells de¢cient in Lck fail to
initiate signaling following TCR ligation [1], which
results in a failure of T cells to develop in mice lack-
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Abbreviations: 13-OP, 13-oxypalmitic acid; iFCS, inactivated
fetal calf serum; BSA, bovine serum albumin; ERK, extracellular
signal-regulated kinase; PAGE, polyacrylamide gel electrophore-
sis ; PAT, protein:S-acyl transferase; PBS, phosphate-bu¡ered
saline
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ing Lck [2]. Engagement of the TCR activates Lck,
which in turn phosphorylates tyrosine residues within
ITAMs (immunoregulatory tyrosine-based activation
motif) present on subunits of the TCR complex. A
second tyrosine kinase, ZAP-70, is recruited to phos-
pho-ITAMs and activated by Lck resulting in Ca2þ
mobilization and the activation of downstream sig-
naling cascades [3^6].
Lck is localized to the inner surface of the plasma
membrane where it associates with the transmem-
brane co-receptors CD4 and CD8. Acylation of
Lck is critical for its plasma membrane localization
[7]. Lck is both co-translationally myristoylated [8]
and post-translationally palmitoylated [9,10]. N-Ter-
minal myristoylation is necessary, but not su⁄cient
for membrane association [7,11]. Palmitoylation of
cysteines 3 and 5 is essential for plasma membrane
localization, as non-palmitoylated Lck [7,11,12] and
its related family member Fyn [13] are primarily cy-
tosolic and non-palmitoylated Lck no longer associ-
ates with CD4 [14]. S-Acylation is a reversible event
and palmitoyl protein thioesterases have been de-
scribed [15,16].
The importance of the heterogeneous nature of
cellular membranes has become increasingly appreci-
ated in recent years. Biological membranes exist in
distinct phases, where the relatively disordered,
loosely packed phospholipids are disrupted by hy-
drophobic patches of highly ordered glycosphingolip-
ids and cholesterol [17,18]. These glycosphingolipid/
cholesterol-rich patches are insoluble in cold, non-
ionic detergents and have been referred to as glyco-
lipid-enriched membrane microdomains (GEMS), de-
tergent resistant microdomains (DRMs), detergent-
insoluble glycolipid-enriched membranes (DIGs)
and membrane lipid rafts. These detergent resistant
membranes subsequently will be referred to as rafts
following the standard nomenclature recently pro-
posed by Simons and Toomre [18]. The importance
of rafts is underscored by the number of recent re-
ports demonstrating the localization of various sig-
naling proteins within these ordered membrane struc-
tures. From this has emerged the hypothesis that
signals initiating at the TCR emanate from protein
clusters within lipid rafts [19^22].
Within the T cell plasma membrane, acylated sig-
naling molecules (e.g. Lck, Fyn, LAT) and glycosyl-
phosphatidylinositol (GPI)-linked proteins (e.g. Thy-
1, Ly-6, CD59, CD48) are constitutively enriched in
lipid rafts and several non-acylated proteins (most
notably the Lck substrates: the j-chain of the TCR
and ZAP-70) are recruited following TCR engage-
ment [19^22]. In the case of the transmembrane
docking protein LAT, it was demonstrated clearly
that palmitoylation directs membrane-localized
LAT to lipid rafts [23,24]. As mentioned, non-S-ac-
ylated Lck is cytosolic and, therefore, it has not been
possible to use non-palmitoylated point mutants of
Lck to directly test whether palmitoylation regulates
the localization of Lck within the plasma membrane.
However, a transmembrane chimeric version of a
palmitoylation-defective mutant of Lck was not
able to localize to membrane lipid rafts [7]. Interest-
ingly, this Lck chimera was able to initiate signaling
in T cells after forced co-localization with the TCR;
however, more distal signaling events such as extra-
cellular signal-regulated kinase (ERK) MAP kinase
and NF-AT activation were impaired. These results
suggested that palmitoylation and lipid raft localiza-
tion of membrane-associated Lck were not necessary
for the initiation of TCR signaling under specialized
conditions and that Lck localized to non-raft regions
of the plasma membrane can be activated by TCR
engagement.
Recently, it was reported that the palmitate ana-
logue, 2-bromopalmitate, inhibited the acylation
(both myristoylation and to a greater extent palmi-
toylation) of the Lck-related tyrosine kinase Fyn
[25]. Treatment of cells with 2-bromopalmitate re-
sulted in 50% of the Fyn becoming cytosolic and in
a reduction in the amount of Fyn and Lck present in
rafts. This reduction translated into an inhibition of
signaling through the TCR. Presumably, this failure
to signal through the TCR was due to the cytosolic
localization of Fyn and Lck. In order to approach
the function of non-raft-associated Lck, we sought to
generate a more hydrophilic version of Lck that
would retain the ability to associate with the plasma
membrane, but would preferentially localize to the
non-raft regions of the membrane. We chose to use
a less hydrophobic analogue of palmitic acid, 13-oxy-
palmitic acid (13-OP).
Heteroatom substitution of an oxygen for carbon
in fatty acids reduces the hydrophobicity of the fatty
acid while maintaining similar chain lengths and
bond angles [26]. Heteroatom-substituted fatty acid
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analogues of myristic acid with substantially reduced
hydrophobicity were demonstrated to be excellent
substrates for N-myristoyl transferase both in vitro
[26] and in vivo [27]. Recently, S-acylated proteins
typically modi¢ed with palmitic acid were shown to
incorporate oleic, stearic and arachidonic acid on the
same cysteine residues that were normally palmitoyl-
ated [28]. The successful use of g-[125I]iodopalmitic
acid for radiolabeling palmitoylated proteins [29^31]
reinforces the conclusion that like N-myristoyl trans-
ferase, the putative palmitoyl transferase will accept
palmitic acid analogues if the modi¢cation occurs at
a su⁄cient distance from the carboxylic acid group.
2. Materials and methods
2.1. Materials
13-Oxypalmitic acid was provided by Dr. Charles
Pidgeon (Purdue University, West Lafayette, IN,
USA) and was synthesized as described previously
for 13-oxymyristic acid [32] substituting sodium
propoxide in n-propanol for sodium methoxide in
methanol. The following antibodies were used:
monoclonal anti-Lck, monoclonal anti-phosphoERK
and polyclonal anti-CD48 were from Santa Cruz.
Polyclonal anti-LAT and monoclonal anti-phospho-
tyrosine (clone 4G10) were from Upstate Biotechnol-
ogy. Monoclonal anti-c-Cbl was from BD Transduc-
tion Laboratories. Polyclonal anti-CD4 was from the
NIH AIDS Research and Reference Reagent Pro-
gram. Monoclonal anti-CD3 (UCHT1) was from
Pharmingen. Polyclonal anti-Lck used for immuno-
precipitation was described previously [33]. Horse-
radish peroxidase-conjugated cholera toxin B subunit
was from Calbiochem-Novabiochem. g-[127I]-
Iodopalmitic acid was synthesized as reported previ-
ously [34] with modi¢cations. 16-Hydroxyhexadeca-
noic acid was purchased from Aldrich. The tosylate
was prepared in 84% yield by stirring the hydroxy
acid with tosyl chloride in CH2Cl2 and pyridine
under argon for 16 h at room temperature (RT).
Reaction of the tosylate with sodium iodide in dry
acetone at re£ux for 1 h gave g-iodopalmitic acid in
high yield after removal of the salt by ¢ltration and
evaporation of the acetone. The white solid product
was further puri¢ed by recrystallization from ethyl
acetate-hexane and characterized by NMR. All other
reagents were purchased from Sigma unless stated
otherwise.
2.2. Generation of g-[125I]iodopalmitic acid
The radiolabeling exchange reaction was per-
formed as described previously [34] with modi¢ca-
tions. In a 2 ml conical glass tube, 100 nmol of g-
[127I]iodopalmitic acid dissolved in 20 Wl acetone was
added to 3 Wl glacial acetic acid. The mixture was
treated with 10 mCi of Na125I (17.4 Ci/mg, NEN) in
500 Wl acetone. The glass tube was sealed with a
rubber septum and submerged into a water bath
equilibrated at 50‡C and incubated for 12 h. The
cooled mixture was transferred to a 15 ml glass
tube containing 2 ml H2O and extracted with 4 ml
of chloroform. The chloroform layer was reduced to
a residue by a stream of nitrogen gas. The residue
was dissolved in 100 Wl of ethanol and injected onto
a Sep-Pak C18 reverse phase column (Waters). The
column was rinsed with 10 ml of water and g-
[125I]iodopalmitic acid was eluted by injecting 10 ml
of acetonitrile. The acetonitrile eluate was dried and
dissolved in 1 ml of chloroform and stored at 320‡C.
Liquid scintillation counting showed that this proce-
dure utilized 48% of available Na125I (an average
yield of ¢ve labeling experiments). The purity of
the product was veri¢ed by TLC analysis [9].
2.3. Cells and cell labeling
The human leukemia T cell line Jurkat (clone E6-
1), the Lck-de¢cient mutant of Jurkat (J.CaM1.6)
and CEM 6 cells were purchased from the American
Type Culture Collection and were grown and main-
tained as described [35]. For treatment with 13-OP,
13-OP was dissolved in 1% dimethyl sulfoxide and a
stock solution of 2 mM 13-OP in RPMI 1640 me-
dium containing 1% fatty acid free bovine serum
albumin (BSA) was prepared. Cells were washed
and incubated for 2 h at 37‡C with RPMI 1640 con-
taining 0.1% fatty acid free BSA and 200 WM 13-OP.
For radiolabeling, Jurkat cells (1U107) were incu-
bated with 0.2 mCi g-[125I]iodopalmitic acid for 2 h
at 37‡C in the presence or absence of 200 WM 13-OP.
Radiolabeled cells were washed and lysed in RIPA
bu¡er (150 mM NaCl, 10 mM Tris/HCl, pH 7.2, 1%
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sodium deoxycholate, 1% Triton X-100, 0.1% sodium
dodecyl sulfate (SDS)) containing 20 Wg/ml each of
the protease inhibitors leupeptin and aprotinin. Ly-
sates were clari¢ed at 100 000Ug for 20 min at 4‡C.
For immunoprecipitation of radiolabeled Lck, RIPA
lysates of Jurkat cells were incubated for 2 h at 4‡C
with rabbit anti-Lck polyclonal antibody bound
to protein A-Sepharose. Immunoprecipitates were
washed three times with RIPA bu¡er. Samples
were dissolved in SDS-sample bu¡er and separated
on 10% SDS-polyacrylamide gels. Gels were dried
and radiolabeled proteins were detected by autora-
diography.
2.4. Subcellular cell fractionation
Subcellular fractionation followed the procedure
of Shenoy-Scaria et al. [36]. Brie£y, Jurkat cells
(2U107) incubated in the presence or absence of
200 WM 13-OP were washed and suspended in hypo-
tonic bu¡er (10 mM Tris, pH 7.4, 0.2 mM MgCl2, 10
Wg/ml aprotinin, 10 Wg/ml leupeptin). After swelling
for 15 min on ice, cells were disrupted with 30
strokes in a tight-¢tting Dounce homogenizer. Ho-
mogenates were adjusted to 0.25 mM sucrose and
1 mM EDTA and centrifuged at 1000Ug. The result-
ing supernatant was centrifuged at 150 000Ug for 60
min at 4‡C. The pellet was dissolved in 1USDS-sam-
ple bu¡er and the supernatant was added to an ap-
propriate volume of 5USDS-sample bu¡er to reach
a ¢nal concentration of 1U. Equal percentages of the
soluble (S) and the particulate (P) samples were sep-
arated on 10% SDS-polyacrylamide gels and ana-
lyzed by immunoblotting with anti-Lck antibody.
2.5. Isolation of rafts
Preparation of rafts was performed as described
previously [24] with some modi¢cations. Jurkat cells
(5U107) incubated for 2 h at 37‡C in the presence or
absence of 200 WM 13-OP were washed and lysed for
15 min in 1 ml ice-cold raft lysis bu¡er (25 mM
MES, pH 6.5, 150 mM NaCl, 1% Triton X-100,
1 mM sodium orthovanadate, 5 mM EDTA, and
20 Wg/ml each of the protease inhibitors, leupeptin
and aprotinin). Subsequent steps were performed at
4‡C. Lysates were homogenized by 10 strokes in a
tight-¢tting Dounce homogenizer, transferred to 5 ml
‘Ultra-Clear’ centrifuge tubes (Beckman Coulter) and
mixed with 1 ml of 80% sucrose in MNE bu¡er (25
mM MES, pH 6.5, 150 mM NaCl, 5 mM EDTA, 20
Wg/ml each of the protease inhibitors aprotinin and
leupeptin and 1 mM sodium orthovanadate) and
overlaid with 2 ml 30% sucrose in MNE followed
by 5% sucrose in MNE. After ultracentrifugation
for 18 h at 200 000Ug in a Beckman SW55Ti rotor,
twelve 400 Wl gradient fractions were collected start-
ing from the top of the gradient. Fractions 2 and 3
containing rafts were combined and added to 200 Wl
5URIPA bu¡er to solubilize rafts. Fractions 10 and
11, representing Triton-soluble lysates, were com-
bined. 20 Wl each of the pooled fractions were sepa-
rated on 6^15% gradient SDS-polyacrylamide gels,
transferred to PVDF membranes and probed with
anti-Lck, anti-LAT, anti-CD48 or anti-c-Cbl anti-
bodies or with horseradish peroxidase-conjugated
cholera toxin B subunit (to detect the ganglioside
GM1).
2.6. Lck-GFP transfection and microscopy
J.CaM1.6 cells were washed twice and suspended
at a concentration of 1.5U107 cells in 500 Wl RPMI
1640 containing 10% inactivated fetal calf serum
(iFCS) with 2.5 Wg Lck-GFP pcDNA3 and 20 Wg
pcDNA3 empty vector. The Lck-GFP vector was
provided by Dr. Anthony Magee (National Institute
for Medical Research, London, UK) and has been
described previously [37]. Cells were electroporated
at 800 WF/250 V using a Cell-Porator (Life Technol-
ogies), and cultured for 18 h in RPMI medium con-
taining 5% iFCS at 37‡C and 5% CO2. Transfected
cells were incubated for 2 h at 37‡C in the presence
or absence of 200 WM 13-OP, washed, seeded onto
coverslips precoated with poly-L-lysine (100 Wg/ml) at
a concentration of 2U105 cells/coverslip and incu-
bated for 10 min at RT. Cells were ¢xed by treating
with 3% paraformaldehyde in phosphate-bu¡ered sa-
line (PBS) for 15 min at RT and washed three times
with PBS. Fluorescence microscopy was performed
24 h later as described previously [38].
2.7. Lck co-immunoprecipitation with CD48 and CD4
CEM 6 cells (2U107) incubated for 2 h at 37‡C in
the presence or absence of 200 WM 13-OP were
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washed and lysed in ice-cold lysis bu¡er containing
0.5% Triton X-100, 20 mM Tris/HCl, pH 7.6, 150
mM NaCl, and 20 Wg/ml each of leupeptin and apro-
tinin. Lysates were clari¢ed by centrifugation at
13 000Ug for 15 min at 4‡C. Supernatants were in-
cubated for 2 h at 4‡C with anti-CD48, anti-CD4 or
anti-Lck polyclonal antibodies bound to protein-A-
Sepharose. Immunoprecipitates were washed three
times with lysis bu¡er, dissociated with SDS-sample
bu¡er, separated on 10% SDS-polyacrylamide gels
and analyzed by immunoblotting for Lck. For im-
munoblot analysis of CD48 and CD4, 10 Wl of ly-
sates were separated on non-reducing 10% SDS-poly-
acrylamide gels and immunoblotted using anti-CD48
and anti-CD4 polyclonal antibodies.
2.8. T cell activation
Jurkat T cells incubated for 2 h at 37‡C in the
presence or absence of 200 WM 13-OP were washed
and resuspended in serum free RPMI at a concen-
tration of 1U107 cells/ml. Cells were activated with
anti-CD3 (0.1 mg/ml) for 3 min at 37‡C. Cells were
washed and lysed in lysis bu¡er containing 1% Tri-
ton X-100, 20 mM Tris/HCl, pH 7.6, 150 mM NaCl,
20 Wg/ml each of leupeptin and aprotinin, 1 mM
pyrophosphate, 1 mM glycerol phosphate, and
1 mM sodium orthovanadate. Samples were sepa-
rated on 6^15% gradient SDS-polyacrylamide gels
and analyzed by immunoblotting with anti-phos-
photyrosine, anti-phosphoERK or anti-c-Cbl anti-
bodies.
3. Results
3.1. Lck from cells treated with 13-OP remains
membrane-associated
Our goal was to generate a less hydrophobic ver-
sion of Lck that still associated with the plasma
membrane in order to test whether a change in the
hydrophobicity of Lck would be su⁄cient to redirect
its localization within the plasma membrane. Specif-
ically we were interested in determining whether a
more hydrophilic version of Lck would relocalize
to the non-raft regions of the plasma membrane.
We chose a heteroatom-substituted analogue of pal-
mitic acid, 13-OP, based on the reported incorpora-
tion into protein of similar heteroatom-substituted
analogues of myristic acid [26,27].
We initially determined that concentrations of 13-
OP at 500 WM or higher resulted in a decrease in the
protein level of Lck, while levels were una¡ected by
treatment with 200 WM 13-OP. In order to determine
whether Lck from cells treated with 13-OP was still
associated with the membrane fraction, we fraction-
ated control and 13-OP-treated Jurkat cells into solu-
ble and particulate fractions and tested each fraction
for the presence of Lck. As can be seen in Fig. 1, Lck
from cells treated with 13-OP was localized exclu-
sively to the particulate fraction, similar to Lck in
control, untreated cells. These results strongly sug-
gested that in 13-OP-treated cells, Lck was still S-
acylated as non-S-acylated Lck previously was found
predominately in the soluble fraction, not associated
with the membrane fraction [7,11].
3.2. Treatment with 13-OP inhibits incorporation of
g-[125I]iodopalmitic acid into Lck
In order to test whether Lck was still palmitoyl-
ated in cells treated with 13-OP, Jurkat cells were
labeled simultaneously with 13-OP and g-[125I]iodo-
palmitic acid for 2 h. It should be noted that this
study was greatly facilitated by the use of g-[125I]-
iodopalmitic acid instead of the commercially avail-
able [3H]palmitic acid due to the greater sensitivity it
o¡ers for the detection of acylated Lck. As shown in
Fig. 2, 13-OP dramatically inhibited both the overall
incorporation of g-[125I]iodopalmitate into cellular
acylated proteins (Fig. 2A) and speci¢cally into Lck
Fig. 1. Lck associates with the membrane fraction in cells
treated with 13-OP. Jurkat cells were incubated with 200 WM
13-OP (+) or with control medium (3) for 0, 3, and 6 h at
37‡C and fractionated into particulate (P) and soluble (S) frac-
tions. Equal aliquots of each fraction were separated by SDS^
polyacrylamide gel electrophoresis (PAGE), transferred to
PVDF membranes and immunoblotted with anti-Lck antibody.
This experiment was performed twice with similar results.
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(Fig. 2B). The analogue had no e¡ect on the incor-
poration of [3H]myristic acid into Lck indicating that
13-OP was neither a substrate nor an inhibitor of N-
myristoyl transferase (data not shown). These results
demonstrated that in the presence of 13-OP, Lck no
longer incorporated iodopalmitic acid. Based on the
incorporation into cellular protein of an equivalent
heteroatom-substituted myristic acid analogue [27]
and the fact that in 13-OP-treated cells Lck remains
associated with the membrane, we conclude that 13-
OP serves as an alternative substrate and S-acylates
Lck resulting in a less hydrophobic version of Lck.
3.3. Treatment with 13-OP prevents Lck localization
to rafts
Palmitoylation of juxtamembrane cysteine residues
has been implicated as a targeting signal for raft
localization of the T cell signaling molecules Lck,
Fyn and LAT. Therefore once we established that
Lck in cells treated with 13-OP was still membrane-
associated, we addressed the question of whether it
was still localized to rafts. Jurkat cells were treated
with 13-OP or with control medium for 2 h, washed,
lysed, and subjected to a sucrose density gradient
centrifugation to isolate raft and non-raft fractions.
Fractions representing rafts (fractions 2 and 3) were
combined as were fractions representing non-raft re-
gions (fractions 10 and 11) and analyzed by immu-
noblotting to detect Lck. As shown in Fig. 3A, Lck
localization to lipid rafts was diminished in 13-OP-
treated cells compared with control cells. This 13-
OP-dependent lipid raft depletion of Lck was accom-
panied by a concomitant increase in localization in
non-raft (Triton-soluble) fractions (Fig. 3A) consis-
tent with a redistribution of Lck within the plasma
membrane. A similar result was obtained when the
distribution of the raft-associated, palmitoylated pro-
tein LAT was examined (Fig. 3A), although the
amount of LAT that was increased in the Triton-
Fig. 2. 13-OP inhibits incorporation of g-[125I]iodopalmitic acid
into T cell proteins including Lck. Jurkat cells were incubated
with 0.2 mCi g-[125I]iodopalmitic acid and simultaneously incu-
bated for 2 h at 37‡C with 200 WM 13-OP (+) or with control
medium (3). Cells were washed and lysed in RIPA bu¡er. Ly-
sates were directly separated by SDS^PAGE (A) or immuno-
precipitated with polyclonal anti-Lck antibody or preimmune
(PI) serum (B) and separated by SDS^PAGE. Gels were dried
and analyzed by autoradiography (upper panels). The exposure
time was 1 day. Molecular mass markers (in kDa) and the mi-
gration position of Lck are indicated. Equal aliquots from each
sample were analyzed by immunoblotting for Lck (lower pan-
els). The results shown are representative of three experiments.
Fig. 3. 13-OP relocalizes Lck from rafts to detergent-soluble
fractions. Jurkat cells were incubated for 2 h at 37‡C with 200
WM 13-OP (+) or with control medium (3). (A) Cells were
washed and lysed in 1% Triton at 4‡C. Lysates were subjected
to sucrose density gradient ultracentrifugation to isolate rafts.
Pooled raft fractions (2 and 3) and pooled Triton-soluble frac-
tions (10 and 11) were separated by SDS^PAGE, transferred to
PVDF membranes and immunoblotted to detect Lck, LAT,
CD48 or c-Cbl, or probed with horseradish peroxidase-conju-
gated cholera toxin B subunit to detect the ganglioside GM1.
(B) 13-OP-treated (+) and control cells (3) were lysed in 1%
Triton at 4‡C, separated by SDS^PAGE, transferred to PVDF
membranes and immunoblotted with the appropriate antibody.
The results shown are representative of three experiments.
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soluble fraction was not as high as that seen with
Lck. These results are consistent with the S-acylation
of LAT with 13-OP resulting in a more hydrophilic
version of LAT and its subsequent redistribution
within the membrane. Treatment of cells with 13-
OP did not disrupt the global integrity of the lipid
rafts as demonstrated by the presence of equivalent
amounts of the lipid raft markers GM1 and CD48 in
both 13-OP-treated and non-treated cells (Fig. 3A,
left panel). The 13-OP-mediated relocalization of
Lck was not due to a non-speci¢c fatty acid e¡ect,
since treatment with equal doses of palmitic acid did
not alter Lck lipid raft localization (data not shown).
Immunoblot analysis of c-Cbl was included as a
marker for non-raft fractions and as a loading con-
trol (Fig. 3A, right panel). To insure that treatment
with 13-OP did not alter protein levels, total cell
lysates from treated and non-treated cells were im-
munoblotted for Lck, LAT and c-Cbl (Fig. 3B).
These results indicated that 13-OP inhibited the lo-
calization of the palmitoylated proteins Lck and
LAT to rafts without disrupting the general compo-
sition of rafts.
3.4. Treatment with 13-OP alters the intracellular
localization of Lck
Using £uorescence microscopy, Kabouridis et al.
demonstrated that wild-type Lck was localized to the
plasma membrane and to structures they identi¢ed as
perinuclear vesicles [7]. We used a similar approach
utilizing an Lck-GFP fusion protein to visualize Lck.
This construct was generated by fusing GFP to the
C-terminus of full length Lck and was shown to re-
tain the function and subcellular localization of wild-
type Lck [37]. Jurkat cells lacking functional Lck
(J.CaM1.6 cells) were transiently transfected with
Lck-GFP and treated with 13-OP or with control
medium for 2 h. Cells were washed and examined
by £uorescence microscopy. As shown in Fig. 4,
Lck-GFP in untreated cells was localized to the plas-
ma membrane and to structures similar to the peri-
nuclear vesicles reported by Kabouridis et al. [7]. In
cells treated with 13-OP, however, the localization of
Lck-GFP to the plasma membrane was maintained,
while localization to the perinuclear vesicles was sig-
ni¢cantly reduced. This indicated that modi¢cation
by 13-OP alters the intracellular localization of Lck
and that palmitoylation is important for the local-
ization of Lck to intracellular structures. Similar re-
sults were seen when cells were analyzed by confocal
microscopy (data not shown).
3.5. Treatment with 13-OP inhibits Lck interaction
with CD48 but not with CD4
We next investigated the e¡ect of 13-OP on Lck
interactions with the raft-localized GPI-linked pro-
tein CD48 and with the transmembrane T cell co-
receptor CD4 using CEM T cells, which express
both CD48 and CD4. CEM cells were treated with
control medium or 13-OP for 2 h. Cells were washed,
lysed and CD48 and CD4 were immunoprecipitated
with anti-CD48 or with anti-CD4 antibodies. Immu-
noprecipitates were analyzed by immunoblotting for
Lck. As shown in Fig. 5, treatment with 13-OP abol-
ished the association of Lck with CD48 (Fig. 5A, left
panel), while having no e¡ect on the association of
Lck with CD4 (Fig. 5A, middle panel) or on levels of
immunoprecipitated Lck (Fig. 5A, right panel).
Treatment with 13-OP did not alter the total cellular
protein levels of either CD48 or CD4 (Fig. 5B). Since
in the human CEM cell line CD4 is predominantly
localized in the non-raft, detergent-soluble fraction
(Fig. 5C), these results are consistent with 13-OP
causing the relocalization of Lck to the non-raft frac-
tion, thereby disrupting its association with raft-lo-
calized CD48, but not with non-raft region-localized
CD4. The results also demonstrate that in CEM
cells, raft localization is not necessary for the associ-
ation of Lck with CD4.
Fig. 4. 13-OP alters Lck intracellular localization. J.CaM1.6
cells transiently expressing Lck-GFP were incubated for 2 h at
37‡C with 200 WM 13-OP (+) or with control medium (3).
Cells were then examined by £uorescence microscopy. The re-
sults shown are representative of experiments performed two
times.
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3.6. Treatment with 13-OP inhibits T cell antigen
receptor signaling
TCR stimulation results in rapid tyrosine phos-
phorylation of multiple intracellular proteins, activa-
tion of the Ras/ERK signaling pathway and trigger-
ing of a number of other signaling cascades. We
examined the ability of 13-OP to alter TCR signaling
by analyzing TCR-induced tyrosine phosphorylation
and ERK activation. Jurkat cells were treated with
13-OP or with control medium for 2 h, washed and
left unstimulated or stimulated with anti-CD3 anti-
body for 3 min. Cell lysates were analyzed by immu-
noblotting with anti-phosphotyrosine antibody. As
shown in Fig. 6 (upper panel), 13-OP-treated cells
showed very little TCR-induced tyrosine phosphory-
lation of proteins compared with control cells. The
same membrane was analyzed for ERK activation by
reprobing with anti-phosphoERK antibodies. As
shown in Fig. 6 (middle panel), 13-OP-treated cells
showed a marked reduction in TCR-induced ERK
activation compared with control cells. The c-Cbl
protein was used as a gel loading control (Fig. 6,
lower panel). Flow cytometric analysis showed sim-
ilar levels of surface expression of the TCR in control
and 13-OP-treated cells (data not shown). These re-
sults demonstrate that 13-OP inhibited TCR signal
transduction consistent with the displacement of Lck
from the rafts.
4. Discussion
This study examined the e¡ects of 13-OP, an oxy-
gen-substituted analogue of palmitic acid on the sub-
cellular localization and function of Lck. 13-OP in-
hibited the palmitoylation of Lck and other T cell
proteins. This inhibition can be explained by two
alternative mechanisms. One possibility is that 13-
OP inhibited the palmitoylation reaction, while the
Fig. 5. 13-OP inhibits Lck association with CD48 but not with
CD4. CEM 6 cells were incubated for 2 h at 37‡C with 200
WM 13-OP (+) or with control medium (3), washed and lysed.
(A) Proteins were immunoprecipitated with polyclonal anti-
CD48, anti-CD4 or anti-Lck antibodies. Immunoprecipitates
were separated by SDS^PAGE and analyzed by immunoblot-
ting with anti-Lck antibody. (B) Lysates from 13-OP-treated
(+) and control cells (3) were separated by SDS^PAGE and
analyzed by immunoblotting with anti-CD48 or anti-CD4 anti-
bodies. (C) CEM cells were lysed in 1% Triton at 4‡C. Lysates
were subjected to sucrose density gradient ultracentrifugation to
isolate rafts. Gradient fractions (1^12) were separated by SDS^
PAGE, transferred to PVDF membranes and immunoblotted to
detect CD4. This experiment was performed twice with similar
results. Fractions 2^4 contain rafts while Triton-soluble proteins
are found in fractions 7^12.
Fig. 6. 13-OP inhibits TCR-induced tyrosine phosphorylation
and ERK activation. Jurkat cells were incubated for 2 h at
37‡C with 200 WM 13-OP or with control medium (Cont.).
Cells were washed, left inactivated (3) or activated (+) with
anti-CD3 antibody for 3 min and lysed. Samples were separated
by SDS^PAGE, transferred to PVDF membranes and immuno-
blotted with anti-phosphotyrosine (upper panel), anti-active
ERK (middle panel), and anti-c-Cbl (lower panel) antibodies.
Molecular mass markers (in kDa) are indicated. This experi-
ment was performed twice with similar results.
BBAMCR 14843 3-5-02
I.Y. Hawash et al. / Biochimica et Biophysica Acta 1589 (2002) 140^150 147
other is that 13-OP served as an alternative substrate
for the putative protein:S-acyl transferase (PAT) re-
sponsible for the palmitoylation of Lck. The ¢rst
possibility would result in a non-S-acylated form of
Lck, while the second would result in an alternatively
S-acylated form of Lck where 13-OP would modify
cysteines 3 and 5 instead of palmitate. Based on the
following evidence, we conclude that 13-OP serves as
an alternative substrate for PAT and generates a
form of Lck that is less hydrophobic than palmito-
ylated Lck. Non-S-acylated Lck is cytosolic and is
found in the soluble fraction when cells are lysed and
fractionated in the absence of detergent [7,11]. How-
ever, in cells treated with 13-OP, Lck remained asso-
ciated with the membrane and fractionated with the
particulate fraction. Non-S-acylated Lck no longer
associates with CD4 [14] and the CD4-Lck associa-
tion remained intact in cells treated with 13-OP.
Thus, it seems reasonable to conclude that 13-OP
does not inhibit PAT, but rather serves as an alter-
native substrate. This conclusion is strengthened by
the recent ¢ndings that in cells, fatty acids in addi-
tion to palmitic acid formed thioester linkages with
cellular proteins [39], including Src family kinases
[28], and by the demonstration that a similar oxy-
gen-substituted myristic acid analogue, 13-oxymyris-
tate, served as an alternative substrate for N-myris-
toyl transferase and became incorporated into
cellular proteins [27]. Finally the successful use of
g-[125I]iodopalmitic acid to label palmitoylated pro-
teins ([13,29^31] and this report) demonstrates that
palmitic acid analogues are substrates for T cell
PAT. Alternatively, the modi¢cation of Lck by 13-
OP could conceivably be non-enzymatic as has been
reported for the palmitoylation reaction [40,41].
Treatment of cells with 13-OP displaced Lck from
the raft, detergent resistant membrane fraction to the
detergent-soluble membrane fraction resulting in an
inhibition of signaling through the TCR. We there-
fore have generated a novel reagent that allows Lck
to remain at the membrane, but speci¢cally excluded
from rafts. This is important because, as mentioned
above, non-palmitoylated versions of Lck where cys-
teines 3 and 5 are replaced with alanines are soluble
[7,11] and it is, therefore, not possible to use this
mutational approach to investigate the function of
membrane-associated Lck that is not localized to
rafts. Additionally, inhibitors of protein S-acyl trans-
ferases are likely to generate cytosolic versions of
Lck [25], which will not be useful for studying the
function of Lck that is localized to the non-raft re-
gions of the plasma membrane. It should be noted
that a 2 h treatment with 13-OP is su⁄cient to dis-
place Lck from lipid rafts. This suggests that the
turnover rate of palmitate on Lck is quite rapid,
which is consistent with observations showing that
[3H]palmitate on Lck has a half-life of 1^2 h in Jur-
kat cells (C.S. Jackson, S.C. Ley and A.I. Magee,
personal communication).
Recently Liang et al. reported that the Src family
member Fyn, which is also present in T cells, is S-
acylated in vivo by long chain dietary unsaturated
fatty acids [28]. The substitution of long chain unsat-
urated fatty acids for palmitate on Fyn resulted in
reduced raft localization [28]. Others, however, have
concluded that long chain dietary unsaturated fatty
acids alter the composition of rafts and it is this
alteration that is responsible for the displacement
of Src family kinases [42]. Mo¡ett et al. reported
that the introduction of an unsaturated acyl chain
into the G protein, GKi, reduced its association
with rafts [43]. These ¢ndings together with the re-
sults reported here using the heteroatom-substituted
palmitic acid analogue, 13-OP, suggest that fatty
acids in addition to palmitic acid are substrates for
cellular PATs and that the nature of the fatty acid
modi¢cation regulates the distribution of S-acylated
proteins within the plasma membrane. It is impor-
tant to note that at least in the human Jurkat T cell
line, Lck is localized both within and outside of rafts
in the membrane ([24] and this manuscript) and the
function of Lck that is associated with the non-raft
regions of the plasma membrane has not been di-
rectly investigated. 13-OP may provide a useful tool
to address this issue.
One consequence of substituting 13-OP for palmi-
tate is to substantially reduce the overall hydropho-
bicity of Lck without signi¢cantly changing acyl
chain length [26]. A less hydrophobic version of
Lck would be predicted to associate less readily
with the hydrophobic rafts. However, it has been
suggested that it is the packing order of the acyl
chains, rather than their hydrophobicity that is the
predominant force targeting acylated proteins to lip-
id rafts [44]. Although the bond angles in the palmi-
tate and 13-oxypalmitate chain are predicted to be
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very similar [26], it is possible that the substituted
oxygen will have a deleterious e¡ect on the tight
acyl chain packing that is thought to de¢ne the lipid
ordered environment of rafts [17]. Our results do not
distinguish between these two models and it is pos-
sible that both reduced hydrophobicity and less or-
dered lipid packing contribute to the relocalization of
Lck in cells treated with 13-OP.
The ¢nding that 13-OP disrupted the association
of Lck with CD48, but not with CD4 is consistent
with the displacement of Lck from rafts. CD48 is a
GPI-linked protein that is present in the outer lea£et
of rafts [45,46], while CD4 is a transmembrane pro-
tein that is predominately localized outside of rafts at
least in some T cell lines [47]. Analysis of CD4 local-
ization in the CEM cells used in this study demon-
strated that CD4 was found predominantly in the
non-lipid raft fraction. Although CD48 is found in
the outer lea£et of the bilayer and Lck is found in
the inner lea£et, their co-localization within rafts
promotes their co-immunoprecipitation. Lck that is
displaced from rafts would be expected to no longer
associate with CD48, while its association with CD4
would be una¡ected.
The ¢nding that 13-OP treatment resulted in a fail-
ure to activate ERK MAP kinase in response to
TCR ligation is consistent with results from Kabour-
idis et al. [7] where a membrane-targeted, non-acyl-
ated chimeric form of Lck that did not associate with
rafts also failed to support activation of ERK MAP
kinase. Our results are also consistent with those of
Webb and colleagues, who demonstrated that dis-
placement of Lck from rafts resulted in a failure to
signal through the TCR [25]. However, this approach
utilized an inhibitor of palmitoylation that likely re-
sulted in a non-palmitoylated, cytosolic version of
Lck, similar to versions of Lck containing mutated
cysteines at residues 3 and 5. Thus, 13-OP may prove
to be a useful reagent for studying TCR-induced
signaling in cells where Lck is still associated with
the plasma membrane, but speci¢cally excluded
from membrane rafts.
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